Pressure cycling technology: a novel approach to virus inactivation in plasma

被引:36
作者
Bradley, DW
Hess, RA
Tao, F
Sciaba-Lentz, L
Remaley, AT
Laugharn, JA
Manak, M
机构
[1] BBI Biotech Res Labs Inc, Gaithersburg, MD 20877 USA
[2] BBI BioSeq Inc, Woburn, MA USA
[3] BMA Labs, Woburn, MA USA
[4] NIH, Dept Clin Pathol, Bethesda, MD 20892 USA
关键词
D O I
10.1046/j.1537-2995.2000.40020193.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Hydrostatic-pressure virus inactivation is a novel approach to the inactivation of pathogens in plasma and blood-derived components, that retains the therapeutic properties of these products. STUDY DESIGN AND METHODS: A custom-built apparatus was used to pressurize human plasma samples spiked with lambda phage. Phage titer and plasma protein activities were monitored after pressure treatment. RESULTS: Pressure-mediated inactivation of lambda phage was found to be an effective means for virus inactivation, particularly when performed at near-zero (0 degrees C) temperatures, rather than at temperatures above 20 degrees C and below -40 degrees C. The efficiency of inactivation was improved by an increase in applied pressure and repeated cycling from atmospheric to high pressure. In contrast, activities of plasma proteins alkaline phosphatase and total amylase did not vary with temperature and remained within 29 percent and 6 percent, respectively, of starting values after the same pressure treatments. By combining cycling, near-zero temperatures, and high pressure, phage titers in serum were reduced approximately 6 log after 10 to 20 minutes of treatment. Activities of plasma proteins IgG, IgM, and factor X were at 104 percent, 89 percent, and 80 percent, respectively, of starting values after 20 minutes of the same temperature and pressure treatment. CONCLUSION: High-pressure procedures may be useful for the inactivation of viruses in blood and other protein-containing components.
引用
收藏
页码:193 / 200
页数:8
相关论文
共 39 条
[1]  
*ABB LAB DIAGN DIV, 1999, ANT CYT CMV ABB CMV, P1
[2]   Emerging viruses in blood transfusion [J].
Allain, JP .
VOX SANGUINIS, 1998, 74 :125-129
[3]   Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood [J].
AuBuchon, JP ;
Birkmeyer, JD ;
Busch, MP .
TRANSFUSION, 1997, 37 (01) :45-51
[4]  
Ausubel FM, 1995, SHORT PROTOCOLS MOL
[5]   Safety of blood products derived from plasma pools: The positive impact of anti-HCV screening on the quality of such products [J].
Cardoso, MD ;
Koerner, K ;
Epple, S ;
Kubanek, B .
VOX SANGUINIS, 1996, 71 (03) :184-186
[6]   Transmission of parasites by blood transfusion [J].
Dodd, RY .
VOX SANGUINIS, 1998, 74 :161-163
[7]  
FERRAOGONZALES F, 1997, HIGH PRESSURE RES BI, P95
[8]   Partially folded states of the capsid protein of cowpea severe mosaic virus in the disassembly pathway [J].
Gaspar, LP ;
Johnson, JE ;
Silva, JL ;
DaPoian, AT .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 273 (02) :456-466
[9]   Effect of high hydrostatic pressure on Escherichia coli and Pseudomonas fluorescens strains in ovine milk [J].
Gervilla, R ;
Felipe, X ;
Ferragut, V ;
Guamis, B .
JOURNAL OF DAIRY SCIENCE, 1997, 80 (10) :2297-2303
[10]   Photosensitized inactivation of Plasmodium falciparum- and Babesia divergens-infected erythrocytes in whole blood by lipophilic pheophorbide derivatives [J].
Grellier, P ;
Santus, R ;
Mouray, E ;
Agmon, V ;
Maziere, JC ;
Rigomier, D ;
Dagan, A ;
Gatt, S ;
Schrevel, J .
VOX SANGUINIS, 1997, 72 (04) :211-220